This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cory, J. G. Articles by Carter, G. L. Search for Related Content PubMed PubMed Citation Articles by Cory, J. G. Articles by Carter, G. L.

Leukemia L1210 Cell Lines Resistant to Ribonucleotide Reductase Inhibitors¹

Division of Medical Oncology, Department of Internal Medicine, University of South Florida College of Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612

Leukemia L1210 cell lines, ED1 and ED2, were generated which were resistant to the cytotoxic effects of deoxyadenosine/erythro-9-(2-hydroxyl-3-nonyl)adenine and deoxyadenosine/erythro-9-(2-hydroxyl-3-nonyl)adenine plus 2,3-dihydro-1H-pyrazole[2,3a]imidazole/Desferal, respectively. The ED1 and ED2 were characterized to show that these cell lines had increased levels of ribonucleotide reductase as measured by CDP reduction. The reductase activity in crude cell-free extracts from the ED1 and ED2 cells was not inhibited by dATP. For CDP reductase, the activation by adenylylimido diphosphate and inhibition by dGTP and dTTP in these extracts from the ED1 and ED2 cells were the same as for the wild-type L1210 cells. The ED1 and ED2 cells were highly cross-resistant, as measured by growth inhibition, to deoxyguanosine/8-aminoguanosine, 2-fluorodeoxyadenosine, and 2-fluoroadenine arabinoside. While the ED2 cells showed resistance to 2,3-dihydro-1H-pyrazole-[2,3a]-imidazole/Desferal (6-fold), the ED1 and ED2 cell lines showed less resistance to hydroxyurea, 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone, and the dialdehyde of inosine. These data indicate that the mechanisms of resistance to the ribonucleotide reductase inhibitors are related to the increased level of ribonucleotide reductase activity and to the decreased sensitivity of the effector-binding subunit to dATP.

¹ This research was supported by grants CA 27398 and CA 42070 from the USPHS, National Cancer Institute, and the Grand Chapter of the Eastern Star.

² To whom requests for reprints should be addressed, at Department of Internal Medicine, MDC Box 19, USF College of Medicine, 12901 Bruce B. Downs Blvd., Tampa, FL 33612.

Received 8/ 3/87. Revised 10/16/87. Accepted 11/13/87.

This article has been cited by other articles:

				N. L. Krett, K. M. Davies, M. Ayres, C. Ma, C. Nabhan, V. Gandhi, and S. T. Rosen 8-Amino-adenosine is a potential therapeutic agent for multiple myeloma Mol. Cancer Ther., November 1, 2004; 3(11): 1411 - 1420. [Abstract] [Full Text] [PDF]